RAVULIZUMAB - Food and Drug Administration
- Set ID
- 82335218-f3f2-4826-a45d-e6cd00a3321c
- Type
- Indexing - product concept
- Effective date
- 2023-03-22
- Version
- 3
- Source
- DailyMed source
Mapped DailyMed Labels#
| Label | Relation | Manufacturer | Effective |
|---|---|---|---|
| These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS ® (ravulizumab-cwvz) injection, for intravenous use Initial U.S. Approval: 2018 | Product name | Alexion Pharmaceuticals Inc. | 2026-10-29 |
| These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS ® (ravulizumab-cwvz) injection, for intravenous use Initial U.S. Approval: 2018 | Product name | Alexion Pharmaceuticals Inc. | 2025-10-09 |
| These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS ® (ravulizumab-cwvz) injection, for intravenous use Initial U.S. Approval: 2018 | Product name | Alexion Pharmaceuticals Inc. | 2024-09-24 |